Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

7.5%

21 terminated/withdrawn out of 279 trials

Success Rate

91.9%

+5.4% vs industry average

Late-Stage Pipeline

33%

91 trials in Phase 3/4

Results Transparency

41%

97 of 239 completed trials have results

Key Signals

10 recruiting97 with results18 terminated

Enrollment Performance

Analytics

Phase 1
82(33.7%)
Phase 2
59(24.3%)
Phase 3
55(22.6%)
Phase 4
36(14.8%)
N/A
9(3.7%)
Early Phase 1
2(0.8%)
243Total
Phase 1(82)
Phase 2(59)
Phase 3(55)
Phase 4(36)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (279)

Showing 20 of 279 trials
NCT05355818Phase 3Completed

Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema

Role: lead

NCT03995550Phase 1Withdrawn

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single and Multiple Doses of LEO 142397 in Healthy People, Including Japanese

Role: lead

NCT05682976Completed

Ophthalmological Adverse Events of Tralokinumab in AD

Role: collaborator

NCT02664805Phase 2Completed

Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema

Role: lead

NCT04361136Phase 1Completed

Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib Cream

Role: lead

NCT05050279Early Phase 1Completed

A Trial to Evaluate the Effect of Delgocitinib on the Heart Rhythm of Healthy People

Role: lead

NCT04807751Phase 1Completed

Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib Cream

Role: lead

NCT05682352Phase 1Completed

Investigating the Safety of LEO 158968 in Healthy Volunteers

Role: lead

NCT03673527Phase 1Completed

Tacrolimus Blood Levels After Topical Application of Tacrolimus on Healthy Skin

Role: lead

NCT04883333Phase 1Completed

A Single and Multiple Ascending-dose Trial of LEO 153339 in Healthy Adults

Role: lead

NCT04306315Phase 4Completed

Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight

Role: lead

NCT04674826Phase 1Completed

A Trial to Compare the Pharmacokinetics of Tralokinumab in Healthy Subjects

Role: lead

NCT06444867Phase 1Completed

A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 158968

Role: lead

NCT07487948Phase 2Not Yet Recruiting

Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris

Role: collaborator

NCT05295732Phase 3Completed

The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis

Role: collaborator

NCT06311682Phase 3Recruiting

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

Role: lead

NCT07013201Phase 2Recruiting

A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

Role: lead

NCT07444801Recruiting

Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact

Role: collaborator

NCT07335588Phase 3Not Yet Recruiting

A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus

Role: lead

NCT05923099Phase 2Completed

A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

Role: lead